Additionally, combination immunotherapy (vs. monotherapy), the use of PD-1 inhibitors (vs. PD- L1 inhibitors), and the use of ICI as a first-line therapy (vs. second-line or further) are also associated with a higher risk of CIP [93]. This evidence concerns the gene PDCD1 and hereditary sensory and autonomic neuropathy.